Swiss National Registry of Grown up Congenital Heart Disease Patients
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Oct 2, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Swiss National Registry of Grown up Congenital Heart Disease Patients is a study designed to better understand the health needs of adults who were born with congenital heart disease. Thanks to advances in pediatric heart surgery and care, most children with this condition now live into adulthood. However, we still need to learn more about the long-term health issues these adults face and the best ways to treat them. The registry will collect important information from patients treated at specialized heart centers in Switzerland to improve care for this growing group of adults.
To participate in this study, you must be an adult over 18 years old with a diagnosis of congenital heart disease, and you should have received treatment at one of the specialized centers in Switzerland. If you are a parent or guardian of someone with trisomy 21 (Down syndrome), you will need to provide consent for them to participate. By joining this registry, you will help researchers gather valuable data that may lead to better healthcare strategies for adults with congenital heart disease in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (above 18 years of age) with congenital heart disease, treated in one of the Swiss centre with specialized organisation for GUCH patients.
- • Signed informed consent. Patients with trisomy 21: the parents or legal guardian will have to give the consent.
- Exclusion Criteria:
- • None
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Lausanne, , Switzerland
Basel, , Switzerland
Bern, , Switzerland
Geneva, , Switzerland
St Gallen, , Switzerland
Patients applied
Trial Officials
Daniel Tobler, MD
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials